Every 8-K that GeoVax Labs, Inc. Warrants (GOVXW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow GOVXW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GOVXW filings page.
GeoVax Labs, Inc. entered into a private placement with institutional investors for approximately $3 million in gross proceeds, issuing 2,027,027 pre-funded warrants and 4,054,054 common warrants priced at $1.4799 per pre-funded warrant and accompanying common warrants.
The pre-funded warrants are exercisable immediately at $0.0001/share until fully exercised, while the common warrants, split into Series A and Series B, are exercisable immediately at $1.48/share with five-year and 18‑month terms, respectively. Net proceeds of about $2.7 million are earmarked for working capital and general corporate purposes.
The unregistered securities were issued under Section 4(a)(2) and Rule 506 of Regulation D, with A.G.P./Alliance Global Partners receiving a 7% cash fee plus expense reimbursements as placement agent. Warrant exercises are subject to a beneficial ownership cap of 4.99%, or 9.99% at the holder’s option.
GeoVax Labs reported a first quarter 2026 net loss of $5.3 million, similar to the $5.4 million loss a year earlier. Revenue fell to zero from $1.6 million in first quarter 2025 after termination of its BARDA/RRPV government contract for the GEO-CM04S1 COVID-19 program.
Research and development expenses declined to $3.9 million from $5.4 million, and general and administrative costs fell to $1.4 million from $1.7 million. Cash and cash equivalents were $1.3 million as of March 31, 2026, down from $3.1 million at December 31, 2025, with stockholders’ equity at $0.5 million.
Operationally, GeoVax highlighted plans to initiate an EMA-supported Phase 3 immunobridging trial for its GEO-MVA mpox/smallpox vaccine in the second half of 2026 and continued positioning of its Gedeptin® immuno-oncology platform, including an exclusive license from Emory University covering combinations with immune checkpoint inhibitors.
GeoVax Labs, Inc. entered into a warrant inducement transaction with institutional investors, who agreed to immediately exercise existing warrants to purchase 501,144 shares of common stock for gross cash proceeds of approximately $595,000, before fees and expenses.
In return, the investors will receive new unregistered warrants to purchase up to 1,002,288 shares of common stock at an exercise price of $1.65 per share. The new warrants will become exercisable after shareholder approval of the underlying shares and will expire five years after that approval date. GeoVax engaged A.G.P./Alliance Global Partners as exclusive financial advisor, paying a 7.0% cash fee on gross proceeds and reimbursing up to $40,000 of legal expenses.
GeoVax Labs, Inc. reported 2025 results showing a smaller annual loss alongside lower research spending as it advanced its GEO-MVA mpox/smallpox vaccine toward a pivotal Phase 3 trial planned for the second half of 2026.
For the year ended December 31, 2025, net loss was $21.5 million, or $22.40 per share, improving from a net loss of $25.0 million, or $120.46 per share, in 2024. Revenue from a government contract related to the BARDA/RRPV Project NextGen award was $2.5 million, down from $4.0 million after BARDA terminated the contract for convenience.
Research and development expenses fell to $18.1 million from $23.7 million, mainly due to discontinued BARDA-related costs and lower GEO-CM04S1 and Gedeptin spending. General and administrative expenses increased to $6.0 million from $5.4 million, driven by higher personnel, investor relations, patent, and stock-based compensation costs. GeoVax ended 2025 with $3.1 million in cash and equivalents and total assets of $6.3 million, compared with $5.5 million in cash and $8.2 million in total assets a year earlier.
GeoVax Labs, Inc. entered into definitive agreements for a registered direct offering of 432,902 shares of common stock or pre-funded warrants at $2.31 per share (or $2.30999 per pre-funded warrant), together with a concurrent private placement of Series A-1 and A-2 common warrants.
The company expects gross proceeds of about $1 million and net proceeds of approximately $865,000, and plans to use the cash for working capital, general corporate purposes and to advance its product candidates. The deal includes 432,902 Series A-1 and 432,902 Series A-2 warrants at a $2.31 exercise price, exercisable after stockholder approval, and a repricing of 236,000 existing warrants down to $2.31 per share.